GASTROINTESTINAL STROMAL TUMOR
Clinical trials for GASTROINTESTINAL STROMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMOR trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare cancers in Largest-Ever trial
Disease control OngoingThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 different rare tumor types. The goal was to see if these drugs could shrink tumors and help control the cancer. The trial is no longer recruiting, and results are bein…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 17:02 UTC
-
New hope for drug-resistant stomach cancer: sorafenib shows promise in early trial
Disease control OngoingThis study tested the drug sorafenib in 38 people with advanced gastrointestinal stromal tumor (GIST) that had stopped responding to two standard treatments, imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumor cells grow and by cutting off blood supply to …
Matched conditions: GASTROINTESTINAL STROMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:13 UTC
-
Experts unite to make cancer trial results easier to compare
Knowledge-focused OngoingThis study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:54 UTC